876461-55-1

Basic information

• Product Name: (S)-3-Amino-1-Cbz-piperidine
• Synonyms: (S)-3-Amino-1-Cbz-piperidine;(3S)-3-Amino-1-piperidinecarboxylic acid phenylmethyl ester;(3S)-3-Amino-1-Cbz-piperidine;Benzyl (3S)-3-aminopiperidine-1-carboxylate;Benzyl (S)-3-aminopiperidine-1-carboxylate
• CAS NO: 876461-55-1
• Molecular Formula: C₁₃H₁₈N₂O₂
• Molecular Weight: 234.3
• Product Categories: Piperidine Series
• Mol File: 876461-55-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 367.2±42.0 °C(Predicted)
• Appearance: /
• Density: 1.151±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.33±0.20(Predicted)
• CAS DataBase Reference: (S)-3-Amino-1-Cbz-piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-Amino-1-Cbz-piperidine(876461-55-1)
• EPA Substance Registry System: (S)-3-Amino-1-Cbz-piperidine(876461-55-1)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 876461-55-1(Hazardous Substances Data)

Usage

General Description

(S)-3-Amino-1-Cbz-piperidine, also known as N-(S)-Boc-3-aminopiperidine, is a chemical compound with a molecular formula of C12H20N2O2. It is a chiral building block used in the synthesis of various pharmaceuticals and other chemical compounds. The compound is a white to off-white solid at room temperature and is commonly used as an intermediate in the production of pharmaceuticals such as velpatasvir, an antiviral medication used to treat chronic hepatitis C. It is also utilized in the creation of other chiral compounds and in pharmaceutical research and development. Additionally, (S)-3-Amino-1-Cbz-piperidine has potential applications in the study of organic chemistry and as a reagent in organic synthesis.

Upstream product

• 876379-22-5 benzyl (3S)-3-[(2-methylpropan-2-yl)oxycarbonylamino]piperidine-1-carboxylate 
• 501-53-1 benzyl chloroformate 
• 216854-23-8 tert-butyl (S)-piperidin-3-yl-carbamate 

Downstream Products

• 1270497-05-6 (S)-3-{3-[5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazin-2-yl]-pyridin-2-ylamino}-piperidine-1-carboxylic acid benzyl ester 
• 1361323-51-4 tert-butyl (S)-1-((S)-3,3-dimethyl-1-((S)-1-(4-nitrophenethyl)piperidin-3-ylamino)-1-oxobutan-2-ylamino)-1-oxopropan-2-yl(methyl)carbamate 
• 1361322-73-7 (S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)-N-((S)-1-(4-nitrophenethyl)piperidin-3-yl)butanamide 
• 1361323-52-5 tert-butyl (S)-1-((S)-3,3-dimethyl-1-oxo-1-((S)-1-(4-(trifluoromethyl)phenethyl)piperidin-3-ylamino)butan-2-ylamino)-1-oxopropan-2-yl(methyl)carbamate 
• 1361322-74-8 (S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)-N-((S)-1-(4-(trifluoromethyl)phenethyl)piperidin-3-yl)butanamide 
• 1361322-98-6 (S)-benzyl 3-((S)-2-amino-2-cyclohexylacetamido)piperidine-1-carboxylate hydrochloride 
• 1361322-99-7 (S)-benzyl 3-((S)-2-((S)-2-(tert-butoxycarbonyl(methyl)amino)propanamido)-2-cyclohexylacetamido)piperidine-1-carboxylate 
• 1361323-00-3 tert-butyl (S)-1-((S)-1-cyclohexyl-2-oxo-2-((S)-piperidin-3-ylamino)ethylamino)-1-oxopropan-2-yl(methyl)carbamate 
• 1361322-49-7 (S)-N-((S)-2-((S)-1-benzylpiperidin-3-ylamino)-1-cyclohexyl-2-oxoethyl)-2-(methylamino)propanamide 
• 1361322-50-0 (S)-N-((S)-1-cyclohexyl-2-oxo-2-((S)-1-(3-phenylpropyl)piperidin-3-ylamino)ethyl)-2-(methylamino)propanamide 
• 1361323-01-4 tert-butyl (S)-1-((S)-2-((S)-1-benzoylpiperidin-3-ylamino)-1-cyclohexyl-2-oxoethylamino)-1-oxopropan-2-yl(methyl)carbamate 
• 1361323-02-5 tert-butyl (S)-1-((S)-1-cyclohexyl-2-oxo-2-((S)-1-(2-phenylacetyl)piperidin-3-ylamino)ethylamino)-1-oxopropan-2-yl(methyl)carbamate 
• 1361322-51-1 (S)-N-((S)-2-((S)-1-benzoylpiperidin-3-ylamino)-1-cyclohexyl-2-oxoethyl)-2-(methylamino)propanamide 
• 1361322-52-2 (S)-N-((S)-1-cyclohexyl-2-oxo-2-((S)-1-(2-phenylacetyl)piperidin-3-ylamino)ethyl)-2-(methylamino)propanamide 

Relevant articles and documents

BENZAMIDE DERIVATIVE

The present invention relates to benzamide derivatives represented by formula (I) or pharmaceutically acceptable salts thereof.

Discovery of aminopiperidine-based Smac mimetics as IAP antagonists

A series of structurally unique Smac mimetics that act as antagonists of inhibitor of apoptosis proteins (IAPs) has been discovered. While most previously described Smac mimetics contain the proline ring (or a similar cyclic motif) found in Smac, a key feature of the compounds described herein is that this ring has been removed. Despite this, compounds in this series potently bind to cIAP1 and elicit the expected phenotype of cIAP1 inhibition in cancer cells. Marked selectivity for cIAP1 over XIAP is observed for these compounds, which is attributed to a slight difference in the binding groove between the two proteins and the resulting steric interactions with the inhibitors. XIAP binding can be improved by constraining the inhibitor so that these unfavorable steric interactions are minimized.